{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:25:58Z","timestamp":1791951958982,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["CRG\/2020\/006,376\/BHS"],"award-info":[{"award-number":["CRG\/2020\/006,376\/BHS"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.xphs.2025.103835","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:37:46Z","timestamp":1747222666000},"page":"103835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dissolvable microneedles assisted minimally invasive transcleral delivery of conjugated soluplus nanomicelles targeting retina in the management of retinoblastoma"],"prefix":"10.1016","volume":"114","author":[{"given":"Mudassir","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-7907","authenticated-orcid":false,"given":"Yogesh A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-7567","authenticated-orcid":false,"given":"Kavita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics9020015","article-title":"Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma","volume":"9","author":"Alsaab","year":"2017","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2025.103835_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-016-0451-7","article-title":"Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma","volume":"35","author":"Kim","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.xphs.2025.103835_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijbiomac.2018.01.120","article-title":"Biological macromolecules for ophthalmic drug delivery to treat ocular diseases","volume":"110","author":"Krishnaswami","year":"2018","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"10.1016\/j.xphs.2025.103835_bib0004","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s12098-017-2395-0","article-title":"Retinoblastoma","volume":"84","author":"Rao","year":"2017","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.xphs.2025.103835_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000320015","article-title":"Angiogenesis and vascular endothelial growth factors in intraocular tumors","volume":"46","author":"Missotten","year":"2010","journal-title":"Dev Ophthalmol"},{"issue":"4","key":"10.1016\/j.xphs.2025.103835_bib0006","first-page":"1","article-title":"Evaluation of aflibercept and ziv aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding","volume":"39","author":"Farah","year":"2018","journal-title":"Int J Retina Vitr"},{"key":"10.1016\/j.xphs.2025.103835_bib0007","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","article-title":"Targeting VEGF in eye neovascularization: what\u2019s new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development","volume":"103","author":"Amadio","year":"2016","journal-title":"Pharmacol Res"},{"issue":"00","key":"10.1016\/j.xphs.2025.103835_bib0008","first-page":"1","article-title":"Protein delivery to the back of the eye : barriers, carriers and stability of anti-VEGF proteins","volume":"00","author":"Radhakrishnan","year":"2016","journal-title":"Drug Discov Today"},{"issue":"0","key":"10.1016\/j.xphs.2025.103835_bib0009","first-page":"1","article-title":"Biodegradable microsphere-Hydrogel ocular drug delivery system for controlled and extended release of bioactive aflibercept in Vitro","volume":"0","author":"Liu","year":"2018","journal-title":"Curr Eye Res"},{"issue":"3","key":"10.1016\/j.xphs.2025.103835_bib0010","first-page":"1","article-title":"Aflibercept nanoformulation inhibits VEGF expression in ocular In vitro model : a preliminary report","volume":"6","author":"Gupta","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.xphs.2025.103835_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2018","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2025.103835_bib0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics10010028","article-title":"Ocular drug delivery barriers\u2014Role of nanocarriers in the treatment of anterior segment Ocular diseases","volume":"10","author":"Bachu","year":"2018","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview Ashaben","volume":"2","author":"Patel","year":"2015","journal-title":"World J Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0014","first-page":"82","article-title":"Vadlapudi Aswani Dutt MAK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery","volume":"2","author":"Kishor","year":"2014","journal-title":"Recent Pat Nanomed"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0015","first-page":"1","article-title":"Nanocarrier mediated retinal drug delivery : overcoming ocular barriers to treat posterior eye diseases","volume":"10","author":"Bisht","year":"2017","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"10.1016\/j.xphs.2025.103835_bib0016","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2014.05.031","article-title":"Nanotherapy for posterior eye diseases","volume":"193","author":"Kaur","year":"2014","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.xphs.2025.103835_bib0017","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/17425247.2016.1227783","article-title":"Recent perspectives on the delivery of biologics to back of the eye","volume":"14","author":"Joseph","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2025.103835_bib0018","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2023045298","article-title":"Advanced technologies of drug delivery to the posterior eye segment targeting angiogenesis and ocular cancer","volume":"41","author":"Ansari","year":"2024","journal-title":"Crit Rev Ther Drug Carr Syst"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0019","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-024-02738-5","article-title":"Rapidly dissolving trans-scleral microneedles for intraocular delivery of cyclosporine A","volume":"25","author":"Alrbyawi","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.xphs.2025.103835_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13346-017-0470-8","article-title":"Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles","volume":"8","author":"Bhatnagar","year":"2018","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"10.1016\/j.xphs.2025.103835_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061622","article-title":"Transscleral delivery of dexamethasone-loaded microparticles using a dissolving microneedle array","volume":"15","author":"Fitaihi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2025.103835_bib0022","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.addr.2017.09.008","article-title":"Overcoming ocular drug delivery barriers through the use of physical forces","volume":"126","author":"Huang","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11095-008-9756-3","article-title":"Intrascleral drug delivery to the eye using hollow microneedles","volume":"26","author":"Jiang","year":"2009","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2025.103835_bib0024","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jphp.12152","article-title":"Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants for sustained ocular drug delivery","volume":"66","author":"Thakur","year":"2014","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jop.2010.0037","article-title":"Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study","volume":"27","author":"Palakurthi","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.103835_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125235","article-title":"Functionalization of polymeric nanomicelles and mixed nanomicelles for targeted retinal delivery in the management of retinoblastoma","author":"Ansari","year":"2025","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2025.103835_bib0027","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/03639045.2020.1776317","article-title":"Microneedle ocular patch: fabrication, characterization, and ex-vivo evaluation using pilocarpine as model drug","volume":"46","author":"Roy","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/macromol4020019","article-title":"Microneedles\u2019 Device: design, fabrication, and applications","volume":"4","author":"Oliveira","year":"2024","journal-title":"Macromol"},{"issue":"6","key":"10.1016\/j.xphs.2025.103835_bib0029","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s13346-016-0332-9","article-title":"Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery","volume":"6","author":"Thakur","year":"2016","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"10.1016\/j.xphs.2025.103835_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061622","article-title":"Transscleral delivery of dexamethasone-loaded microparticles using a dissolving microneedle array","volume":"15","author":"Fitaihi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2025.103835_bib0031","unstructured":"Interagency Coordinating Committee on the Validation of Alternative Methods. ICCVAM-recommended test method protocol: hen\u2019s Egg Test-chorioallantoic membrane (HET-CAM) test method. Published online 2010:30\u201338. http:\/\/iccvam.niehs.nih.gov\/methods\/ocutox\/MildMod-TMER.htm."},{"key":"10.1016\/j.xphs.2025.103835_bib0032","first-page":"70","article-title":"Ocular delivery of cyclosporine A using dissolvable microneedle contact lens","author":"Datta","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2025.103835_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116339","article-title":"Mechanical strength affecting the penetration in microneedles and PLGA nanoparticle-assisted drug delivery: importance of preparation and formulation","volume":"173","author":"Lu","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020200","article-title":"Mechanical characterization of dissolving microneedles: factors affecting physical strength of needles","volume":"16","author":"Ando","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2025.103835_bib0035","article-title":"Drug delivery with dissolving microneedles: skin puncture, its influencing factors and improvement strategies","volume":"76","author":"Xiu","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"10.1016\/j.xphs.2025.103835_bib0036","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1877912311202020082","article-title":"Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery","volume":"2","author":"Cholkar","year":"2012","journal-title":"Recent Pat Nanomed"},{"issue":"12","key":"10.1016\/j.xphs.2025.103835_bib0037","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sciera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2025.103835_bib0038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/jop.2007.0061","article-title":"Trans-scleral delivery of antiangiogenic proteins","volume":"24","author":"Demetriades","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2025.103835_bib0039","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.2042-7158.2010.01153.x","article-title":"In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application","volume":"62","author":"Pescina","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2025.103835_bib0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2018","journal-title":"J Control Release"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925002886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925002886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:56Z","timestamp":1777420856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925002886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0022354925002886"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103835","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dissolvable microneedles assisted minimally invasive transcleral delivery of conjugated soluplus nanomicelles targeting retina in the management of retinoblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103835"}}